| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 129 | 2025 | 712 | 14.880 |
Why?
|
| Anti-HIV Agents | 40 | 2025 | 159 | 6.720 |
Why?
|
| Antiretroviral Therapy, Highly Active | 21 | 2020 | 91 | 3.320 |
Why?
|
| Viral Load | 29 | 2024 | 135 | 2.790 |
Why?
|
| Humans | 166 | 2025 | 17376 | 2.490 |
Why?
|
| Anti-Retroviral Agents | 22 | 2025 | 82 | 2.440 |
Why?
|
| Male | 119 | 2025 | 9843 | 2.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 12 | 2023 | 63 | 2.090 |
Why?
|
| Adult | 106 | 2025 | 7529 | 2.050 |
Why?
|
| CD4 Lymphocyte Count | 39 | 2024 | 181 | 2.020 |
Why?
|
| Cohort Studies | 66 | 2025 | 2526 | 1.980 |
Why?
|
| Female | 116 | 2025 | 12444 | 1.960 |
Why?
|
| Middle Aged | 96 | 2025 | 7885 | 1.930 |
Why?
|
| Delivery of Health Care, Integrated | 10 | 2021 | 537 | 1.820 |
Why?
|
| Hepatitis C, Chronic | 6 | 2021 | 75 | 1.460 |
Why?
|
| Neoplasms | 13 | 2025 | 448 | 1.400 |
Why?
|
| Continuity of Patient Care | 7 | 2022 | 104 | 1.380 |
Why?
|
| United States | 46 | 2024 | 3891 | 1.320 |
Why?
|
| Hepatitis C | 7 | 2022 | 64 | 1.240 |
Why?
|
| Delivery of Health Care | 7 | 2022 | 395 | 1.230 |
Why?
|
| RNA, Viral | 17 | 2024 | 65 | 1.210 |
Why?
|
| Life Expectancy | 4 | 2021 | 34 | 1.190 |
Why?
|
| HIV-1 | 15 | 2017 | 71 | 1.190 |
Why?
|
| Patient Compliance | 7 | 2015 | 278 | 1.110 |
Why?
|
| Retrospective Studies | 28 | 2024 | 2428 | 1.110 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 455 | 1.100 |
Why?
|
| Electronic Health Records | 9 | 2024 | 707 | 1.090 |
Why?
|
| Quality of Health Care | 2 | 2020 | 279 | 1.000 |
Why?
|
| Risk Factors | 35 | 2025 | 3255 | 0.890 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2024 | 25 | 0.850 |
Why?
|
| Health Services Accessibility | 7 | 2020 | 274 | 0.850 |
Why?
|
| Algorithms | 3 | 2023 | 226 | 0.840 |
Why?
|
| Coinfection | 5 | 2025 | 31 | 0.800 |
Why?
|
| Healthcare Disparities | 5 | 2017 | 205 | 0.770 |
Why?
|
| Incidence | 24 | 2024 | 1266 | 0.760 |
Why?
|
| Ethnic Groups | 5 | 2021 | 456 | 0.750 |
Why?
|
| Treatment Outcome | 13 | 2022 | 1170 | 0.740 |
Why?
|
| Adolescent | 26 | 2022 | 3533 | 0.730 |
Why?
|
| Aged | 37 | 2024 | 6129 | 0.730 |
Why?
|
| Young Adult | 25 | 2022 | 2473 | 0.710 |
Why?
|
| Continental Population Groups | 2 | 2015 | 289 | 0.700 |
Why?
|
| Diabetic Foot | 1 | 2020 | 3 | 0.700 |
Why?
|
| Hepacivirus | 5 | 2022 | 52 | 0.690 |
Why?
|
| Raltegravir Potassium | 2 | 2018 | 9 | 0.690 |
Why?
|
| California | 24 | 2025 | 2317 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2020 | 380 | 0.650 |
Why?
|
| Anemia | 3 | 2025 | 32 | 0.650 |
Why?
|
| Quality Assurance, Health Care | 2 | 2011 | 134 | 0.650 |
Why?
|
| District of Columbia | 11 | 2024 | 17 | 0.630 |
Why?
|
| Office Visits | 3 | 2021 | 74 | 0.620 |
Why?
|
| Canada | 18 | 2023 | 70 | 0.610 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2021 | 34 | 0.600 |
Why?
|
| Disease Eradication | 1 | 2018 | 3 | 0.590 |
Why?
|
| Appointments and Schedules | 2 | 2021 | 25 | 0.590 |
Why?
|
| Comparative Effectiveness Research | 2 | 2019 | 63 | 0.580 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 96 | 0.570 |
Why?
|
| Sexual and Gender Minorities | 3 | 2024 | 31 | 0.560 |
Why?
|
| Mass Screening | 6 | 2020 | 671 | 0.550 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 533 | 0.540 |
Why?
|
| Primary Health Care | 9 | 2025 | 729 | 0.530 |
Why?
|
| Medication Adherence | 5 | 2020 | 239 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2024 | 185 | 0.510 |
Why?
|
| Dyslipidemias | 2 | 2024 | 56 | 0.500 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 22 | 0.500 |
Why?
|
| Substance-Related Disorders | 6 | 2025 | 424 | 0.490 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 42 | 0.490 |
Why?
|
| Syphilis | 2 | 2020 | 17 | 0.490 |
Why?
|
| Low Back Pain | 1 | 2016 | 57 | 0.480 |
Why?
|
| HIV | 7 | 2023 | 26 | 0.480 |
Why?
|
| Hypertension | 4 | 2024 | 469 | 0.440 |
Why?
|
| North America | 12 | 2024 | 44 | 0.440 |
Why?
|
| Viremia | 2 | 2020 | 9 | 0.430 |
Why?
|
| End Stage Liver Disease | 3 | 2022 | 9 | 0.420 |
Why?
|
| Prevalence | 11 | 2024 | 839 | 0.420 |
Why?
|
| Cross-Sectional Studies | 14 | 2024 | 1287 | 0.420 |
Why?
|
| Insurance Coverage | 4 | 2020 | 103 | 0.420 |
Why?
|
| HIV Seropositivity | 2 | 2017 | 31 | 0.410 |
Why?
|
| Health Services Research | 1 | 2014 | 212 | 0.410 |
Why?
|
| Organophosphorus Compounds | 1 | 2013 | 2 | 0.410 |
Why?
|
| Deoxycytidine | 1 | 2013 | 7 | 0.410 |
Why?
|
| Mental Health | 3 | 2025 | 168 | 0.400 |
Why?
|
| Insurance, Health | 2 | 2020 | 175 | 0.400 |
Why?
|
| African Continental Ancestry Group | 4 | 2017 | 144 | 0.400 |
Why?
|
| Glomerular Filtration Rate | 3 | 2023 | 153 | 0.390 |
Why?
|
| Primary Prevention | 1 | 2013 | 63 | 0.390 |
Why?
|
| Hepatitis B, Chronic | 3 | 2022 | 33 | 0.390 |
Why?
|
| Socioeconomic Factors | 5 | 2024 | 609 | 0.390 |
Why?
|
| HIV Protease Inhibitors | 5 | 2024 | 24 | 0.380 |
Why?
|
| Drug Prescriptions | 4 | 2023 | 148 | 0.370 |
Why?
|
| Contraception | 1 | 2011 | 24 | 0.370 |
Why?
|
| Pregnancy in Diabetics | 1 | 2011 | 17 | 0.370 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 225 | 0.360 |
Why?
|
| Hepatitis B | 2 | 2023 | 45 | 0.360 |
Why?
|
| Transgender Persons | 2 | 2022 | 33 | 0.350 |
Why?
|
| Diabetes Complications | 1 | 2011 | 106 | 0.350 |
Why?
|
| Antiviral Agents | 4 | 2022 | 100 | 0.350 |
Why?
|
| Sarcoma, Kaposi | 3 | 2021 | 12 | 0.350 |
Why?
|
| Health Services Administration | 1 | 2010 | 3 | 0.350 |
Why?
|
| Longitudinal Studies | 7 | 2025 | 677 | 0.350 |
Why?
|
| Organophosphonates | 1 | 2010 | 7 | 0.330 |
Why?
|
| Fanconi Syndrome | 1 | 2010 | 5 | 0.330 |
Why?
|
| Adenine | 1 | 2010 | 8 | 0.330 |
Why?
|
| Proportional Hazards Models | 10 | 2021 | 702 | 0.330 |
Why?
|
| Tenofovir | 4 | 2023 | 18 | 0.330 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2009 | 4 | 0.320 |
Why?
|
| Pyrrolidinones | 1 | 2009 | 4 | 0.320 |
Why?
|
| Peptide Fragments | 1 | 2009 | 28 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 666 | 0.320 |
Why?
|
| Databases, Factual | 3 | 2023 | 306 | 0.310 |
Why?
|
| Gemfibrozil | 1 | 2009 | 5 | 0.310 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 38 | 0.310 |
Why?
|
| Oligopeptides | 1 | 2008 | 7 | 0.310 |
Why?
|
| Pyridines | 1 | 2008 | 9 | 0.310 |
Why?
|
| Alcohol Drinking | 3 | 2021 | 355 | 0.300 |
Why?
|
| Health Policy | 5 | 2016 | 109 | 0.300 |
Why?
|
| Ritonavir | 1 | 2008 | 15 | 0.300 |
Why?
|
| Comorbidity | 8 | 2024 | 564 | 0.300 |
Why?
|
| Models, Theoretical | 2 | 2019 | 66 | 0.300 |
Why?
|
| Mental Disorders | 2 | 2022 | 273 | 0.290 |
Why?
|
| Logistic Models | 6 | 2014 | 884 | 0.290 |
Why?
|
| Depressive Disorder | 2 | 2019 | 185 | 0.290 |
Why?
|
| Community Health Centers | 3 | 2019 | 64 | 0.290 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2008 | 46 | 0.280 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 1942 | 0.280 |
Why?
|
| Hospitalization | 3 | 2022 | 805 | 0.280 |
Why?
|
| Alcoholism | 3 | 2021 | 337 | 0.270 |
Why?
|
| Pharmacists | 1 | 2007 | 48 | 0.270 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 17 | 0.260 |
Why?
|
| Odds Ratio | 5 | 2020 | 644 | 0.250 |
Why?
|
| Disease Progression | 3 | 2023 | 259 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 165 | 0.250 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 538 | 0.250 |
Why?
|
| Drug Resistance, Multiple, Viral | 3 | 2011 | 6 | 0.240 |
Why?
|
| Anus Neoplasms | 4 | 2020 | 27 | 0.240 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 1155 | 0.240 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 42 | 0.240 |
Why?
|
| Age Distribution | 5 | 2021 | 239 | 0.240 |
Why?
|
| Marijuana Abuse | 1 | 2025 | 43 | 0.230 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2022 | 54 | 0.230 |
Why?
|
| Erythrocyte Indices | 1 | 2024 | 2 | 0.230 |
Why?
|
| Social Stigma | 1 | 2024 | 16 | 0.230 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 151 | 0.230 |
Why?
|
| Heart Failure | 2 | 2022 | 404 | 0.220 |
Why?
|
| Research Design | 4 | 2019 | 343 | 0.220 |
Why?
|
| Self Report | 2 | 2025 | 257 | 0.220 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 30 | 0.220 |
Why?
|
| Medical Record Linkage | 2 | 2015 | 37 | 0.220 |
Why?
|
| Health Status Disparities | 2 | 2019 | 148 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 29 | 0.210 |
Why?
|
| Phenotype | 1 | 2024 | 148 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 142 | 0.210 |
Why?
|
| Weight Loss | 3 | 2022 | 295 | 0.210 |
Why?
|
| Age Factors | 6 | 2020 | 884 | 0.210 |
Why?
|
| Epidemics | 2 | 2013 | 6 | 0.200 |
Why?
|
| Fractures, Bone | 1 | 2023 | 94 | 0.200 |
Why?
|
| Treatment Failure | 3 | 2012 | 31 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 52 | 0.200 |
Why?
|
| Lymphoma, AIDS-Related | 3 | 2011 | 18 | 0.200 |
Why?
|
| Dementia | 1 | 2024 | 123 | 0.190 |
Why?
|
| Homosexuality, Male | 3 | 2024 | 38 | 0.190 |
Why?
|
| Herpes Zoster | 2 | 2014 | 82 | 0.190 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 439 | 0.190 |
Why?
|
| Risk Assessment | 6 | 2024 | 1079 | 0.190 |
Why?
|
| Life Tables | 1 | 2021 | 8 | 0.190 |
Why?
|
| Medical Marijuana | 1 | 2022 | 23 | 0.190 |
Why?
|
| Forecasting | 1 | 2022 | 69 | 0.190 |
Why?
|
| Gastric Bypass | 1 | 2022 | 72 | 0.180 |
Why?
|
| Mid-Atlantic Region | 3 | 2021 | 9 | 0.180 |
Why?
|
| Obesity | 2 | 2019 | 814 | 0.180 |
Why?
|
| Health Maintenance Organizations | 3 | 2008 | 408 | 0.180 |
Why?
|
| Health Care Surveys | 1 | 2022 | 218 | 0.180 |
Why?
|
| Hispanic Americans | 3 | 2021 | 378 | 0.180 |
Why?
|
| Infant, Newborn | 2 | 2021 | 805 | 0.180 |
Why?
|
| Smoking | 2 | 2021 | 428 | 0.180 |
Why?
|
| Guideline Adherence | 2 | 2019 | 152 | 0.180 |
Why?
|
| Weight Gain | 2 | 2020 | 156 | 0.180 |
Why?
|
| Time Factors | 5 | 2016 | 1044 | 0.180 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2016 | 216 | 0.180 |
Why?
|
| Amputation | 1 | 2020 | 11 | 0.170 |
Why?
|
| Obesity, Morbid | 1 | 2022 | 121 | 0.170 |
Why?
|
| Tobacco Smoking | 1 | 2021 | 19 | 0.170 |
Why?
|
| Temperature | 1 | 2020 | 19 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2016 | 16 | 0.170 |
Why?
|
| Benchmarking | 1 | 2020 | 41 | 0.170 |
Why?
|
| Managed Care Programs | 2 | 2021 | 309 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2022 | 131 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 2 | 0.170 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2020 | 3 | 0.170 |
Why?
|
| Unsafe Sex | 1 | 2020 | 19 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 311 | 0.170 |
Why?
|
| European Continental Ancestry Group | 3 | 2020 | 480 | 0.170 |
Why?
|
| Gonorrhea | 1 | 2020 | 19 | 0.160 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 23 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2020 | 127 | 0.160 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 30 | 0.160 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 18 | 0.160 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 270 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 35 | 0.160 |
Why?
|
| Phentermine | 1 | 2019 | 10 | 0.160 |
Why?
|
| Appetite Depressants | 1 | 2019 | 16 | 0.160 |
Why?
|
| Creatinine | 3 | 2023 | 66 | 0.160 |
Why?
|
| Motivational Interviewing | 1 | 2019 | 34 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 107 | 0.150 |
Why?
|
| Smoking Cessation | 1 | 2020 | 154 | 0.150 |
Why?
|
| Text Messaging | 1 | 2019 | 34 | 0.150 |
Why?
|
| Overweight | 2 | 2019 | 266 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2020 | 315 | 0.150 |
Why?
|
| Population Surveillance | 3 | 2017 | 254 | 0.150 |
Why?
|
| Body Mass Index | 3 | 2019 | 937 | 0.150 |
Why?
|
| Disease Notification | 1 | 1998 | 7 | 0.140 |
Why?
|
| Sex Distribution | 2 | 2015 | 180 | 0.140 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2014 | 7 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2015 | 26 | 0.140 |
Why?
|
| Referral and Consultation | 2 | 2019 | 160 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 174 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 14 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 182 | 0.140 |
Why?
|
| Living Donors | 1 | 2017 | 3 | 0.140 |
Why?
|
| Graft Rejection | 1 | 2017 | 4 | 0.140 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 10 | 0.140 |
Why?
|
| Gastroenterology | 1 | 2017 | 19 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2017 | 71 | 0.130 |
Why?
|
| Pneumonia | 1 | 2017 | 49 | 0.130 |
Why?
|
| HIV Protease | 2 | 2006 | 4 | 0.130 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 18 | 0.130 |
Why?
|
| Pneumococcal Infections | 1 | 2016 | 44 | 0.130 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 8 | 0.130 |
Why?
|
| Glycated Hemoglobin A | 3 | 2022 | 184 | 0.130 |
Why?
|
| African Americans | 4 | 2021 | 443 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2013 | 280 | 0.130 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 68 | 0.130 |
Why?
|
| Geography | 1 | 2016 | 39 | 0.120 |
Why?
|
| Patient Care | 1 | 2016 | 30 | 0.120 |
Why?
|
| Prognosis | 4 | 2025 | 604 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 36 | 0.120 |
Why?
|
| Sex Factors | 4 | 2020 | 607 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2022 | 1229 | 0.120 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 22 | 0.120 |
Why?
|
| National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2014 | 5 | 0.120 |
Why?
|
| Risk | 4 | 2021 | 498 | 0.110 |
Why?
|
| Safety-net Providers | 1 | 2015 | 55 | 0.110 |
Why?
|
| Neuralgia | 1 | 2014 | 3 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 140 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 76 | 0.110 |
Why?
|
| Internet | 2 | 2013 | 212 | 0.110 |
Why?
|
| Hepatitis C Antibodies | 1 | 2014 | 4 | 0.110 |
Why?
|
| Healthcare Financing | 1 | 2013 | 4 | 0.110 |
Why?
|
| Government Programs | 1 | 2013 | 12 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 977 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 8 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 16 | 0.100 |
Why?
|
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2013 | 3 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 6 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2013 | 43 | 0.100 |
Why?
|
| Survival Rate | 1 | 2013 | 253 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 44 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2012 | 24 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2016 | 203 | 0.100 |
Why?
|
| Drug Resistance, Viral | 2 | 2009 | 12 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 263 | 0.090 |
Why?
|
| Aging | 3 | 2022 | 160 | 0.090 |
Why?
|
| Biomarkers | 1 | 2013 | 306 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2017 | 1100 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2022 | 73 | 0.090 |
Why?
|
| Stroke | 1 | 2014 | 310 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2011 | 24 | 0.090 |
Why?
|
| Urination Disorders | 1 | 2011 | 10 | 0.090 |
Why?
|
| Erectile Dysfunction | 1 | 2011 | 24 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 285 | 0.090 |
Why?
|
| Cooperative Behavior | 3 | 2016 | 90 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 21 | 0.080 |
Why?
|
| Confidentiality | 2 | 2022 | 25 | 0.080 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2009 | 84 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2010 | 45 | 0.080 |
Why?
|
| Hemoglobins | 2 | 2024 | 37 | 0.080 |
Why?
|
| Appendicitis | 1 | 2009 | 14 | 0.080 |
Why?
|
| Mutation | 2 | 2011 | 132 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 197 | 0.080 |
Why?
|
| Atazanavir Sulfate | 1 | 2008 | 5 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 627 | 0.080 |
Why?
|
| Pregnancy | 2 | 2011 | 1466 | 0.080 |
Why?
|
| Triglycerides | 1 | 2009 | 83 | 0.080 |
Why?
|
| Mortality | 1 | 2009 | 116 | 0.080 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2021 | 25 | 0.070 |
Why?
|
| Sustained Virologic Response | 2 | 2019 | 19 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2019 | 25 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 112 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 342 | 0.070 |
Why?
|
| Health Promotion | 1 | 2011 | 278 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 165 | 0.070 |
Why?
|
| AIDS Serodiagnosis | 1 | 2007 | 9 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2020 | 215 | 0.070 |
Why?
|
| Medical Indigency | 1 | 2006 | 4 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2020 | 190 | 0.060 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 529 | 0.060 |
Why?
|
| Drug Information Services | 1 | 2005 | 3 | 0.060 |
Why?
|
| Medication Errors | 1 | 2005 | 6 | 0.060 |
Why?
|
| Drug Utilization Review | 1 | 2005 | 24 | 0.060 |
Why?
|
| Registries | 3 | 2013 | 460 | 0.060 |
Why?
|
| Infant | 2 | 2022 | 1162 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 100 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 70 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2015 | 55 | 0.060 |
Why?
|
| Genotype | 3 | 2011 | 223 | 0.060 |
Why?
|
| Multimorbidity | 1 | 2024 | 12 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 124 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2023 | 18 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 25 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2022 | 12 | 0.050 |
Why?
|
| Patient Participation | 2 | 2015 | 123 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Kidney | 1 | 2023 | 52 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2022 | 47 | 0.050 |
Why?
|
| Gender Identity | 1 | 2022 | 33 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 40 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 92 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 29 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2022 | 128 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2020 | 83 | 0.040 |
Why?
|
| Oxazines | 1 | 2020 | 2 | 0.040 |
Why?
|
| Condoms | 1 | 2020 | 33 | 0.040 |
Why?
|
| Pyridones | 1 | 2020 | 7 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 9 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 41 | 0.040 |
Why?
|
| Immunosuppression | 1 | 2020 | 6 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2020 | 38 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 211 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 72 | 0.040 |
Why?
|
| Mood Disorders | 1 | 2019 | 16 | 0.040 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2019 | 4 | 0.040 |
Why?
|
| Insulin | 1 | 2020 | 190 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 120 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 385 | 0.040 |
Why?
|
| Liver | 1 | 2019 | 34 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 21 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 41 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2021 | 275 | 0.040 |
Why?
|
| Minority Groups | 1 | 2019 | 103 | 0.040 |
Why?
|
| Prediabetic State | 1 | 2019 | 52 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2019 | 100 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 226 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 367 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 181 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 17 | 0.040 |
Why?
|
| Anxiety | 1 | 2019 | 154 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 251 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2019 | 126 | 0.040 |
Why?
|
| Prejudice | 1 | 1998 | 22 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 405 | 0.030 |
Why?
|
| Graft Survival | 1 | 2017 | 2 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2017 | 6 | 0.030 |
Why?
|
| Child | 2 | 2015 | 2382 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 28 | 0.030 |
Why?
|
| Serogroup | 1 | 2016 | 10 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 1287 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 21 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 86 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 59 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 128 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 107 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 250 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 104 | 0.030 |
Why?
|
| Inservice Training | 1 | 2015 | 14 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 96 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 56 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 231 | 0.030 |
Why?
|
| Reminder Systems | 1 | 2015 | 74 | 0.030 |
Why?
|
| Depression | 1 | 2019 | 487 | 0.030 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 311 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2013 | 40 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 13 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 14 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 23 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 9 | 0.030 |
Why?
|
| Reference Values | 1 | 2012 | 86 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 94 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 13 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 200 | 0.020 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2011 | 4 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2011 | 12 | 0.020 |
Why?
|
| Vaccination | 1 | 2016 | 685 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 47 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 12 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1375 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 119 | 0.020 |
Why?
|
| Immunization Programs | 1 | 2011 | 65 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 74 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 56 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 173 | 0.020 |
Why?
|
| Financing, Government | 1 | 2007 | 26 | 0.020 |
Why?
|
| Quality of Life | 1 | 2011 | 505 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 294 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 2 | 0.020 |
Why?
|
| Base Sequence | 1 | 2006 | 18 | 0.020 |
Why?
|
| Nelfinavir | 1 | 2006 | 4 | 0.020 |
Why?
|
| Phylogeny | 1 | 2006 | 15 | 0.020 |
Why?
|
| Research | 1 | 2007 | 61 | 0.020 |
Why?
|
| Medicare | 1 | 2007 | 201 | 0.020 |
Why?
|
| Medicaid | 1 | 2007 | 184 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 151 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 17 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 62 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 193 | 0.010 |
Why?
|